v3.26.1
Revenue - Schedule of Disaggregated Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Disaggregation Of Revenue [Line Items]    
Revenue $ 70,874 $ 52,443
MRD Revenue    
Disaggregation Of Revenue [Line Items]    
Revenue 67,093 43,721
MRD Revenue | Service and Licensing Revenue    
Disaggregation Of Revenue [Line Items]    
Revenue 58,093 39,221
MRD Revenue | Regulatory Milestone Revenue    
Disaggregation Of Revenue [Line Items]    
Revenue 9,000 4,500
Immune Medicine Revenue    
Disaggregation Of Revenue [Line Items]    
Revenue 3,781 8,722
Immune Medicine Revenue | Service and Licensing Revenue    
Disaggregation Of Revenue [Line Items]    
Revenue   5,122
Immune Medicine Revenue | Service and Licensing Revenue    
Disaggregation Of Revenue [Line Items]    
Revenue 3,781  
Immune Medicine Revenue | Collaboration Revenue    
Disaggregation Of Revenue [Line Items]    
Revenue [1] $ 0 $ 3,600
[1] On August 13, 2025, the Genentech Agreement was terminated, with termination effective February 9, 2026.